A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma - the STORM trial

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Witzens Harig, Mathias ^a   Memmer, Marie Luise ^a   Dreyling, Martin ^b   Hess, Georg ^c  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYTARABINE; DEXAMETHASONE; RITUXIMAB; TEMSIROLIMUS; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; MTOR PROTEIN, HUMAN; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

ARTICLE; BLOOD TOXICITY; CANCER RECURRENCE; CANCER RESISTANCE; CLINICAL ARTICLE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEASIBILITY STUDY; GENE EXPRESSION; HUMAN; LARGE CELL LYMPHOMA; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SALVAGE THERAPY; STEM CELL MOBILIZATION; ADULT; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; METHODOLOGY; MORTALITY; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROCEDURES;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CYTARABINE; DEXAMETHASONE; DISEASE-FREE SURVIVAL; FEASIBILITY STUDIES; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MAXIMUM TOLERATED DOSE; NEOPLASM RECURRENCE, LOCAL; RESEARCH DESIGN; SALVAGE THERAPY; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84879240456     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-308     Document Type: Article

References (9)

1. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006, 107(1):265-276. 10.1182/blood-2005-06-2508, 1895348, 16150940.
2. Philip T, Chauvin F, Armitage J, Bron D, Hagenbeek A, Biron P, Spitzer G, Velasquez W, Weisenburger DD, Fernandez-Ranada J, et al. Parma international protocol: pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation. Blood 1991, 77(7):1587-1592.
3. Gisselbrecht CGB, Mounier N, Gill D, Linch D, Trneny M, Bosly A, Shpilberg O, Ketterer N, Moskowitz C, Schmitz N. R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL study. J Clin Oncol 2009, 27:15s. 2009 (suppl; abstr 8509).
4. Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C, Laurell A, Offner F, Strahs A, Berkenblit A, et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009, 27(23):3822-3829. 10.1200/JCO.2008.20.7977, 19581539.
5. Ansell SM, Tang H, Kurtin PJ, Koenig PA, Inwards DJ, Shah K, Ziesmer SC, Feldman AL, Rao R, Gupta M, et al. Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. Lancet Oncol 2011 Apr, 12(4):361-368.
6. Smith SM, Van Besien K, Karrison T, Dancey J, McLaughlin P, Younes A, Smith S, Stiff P, Lester E, Modi S, et al. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium. J Clin Oncol 2010, 28(31):4740-4746. 10.1200/JCO.2010.29.2813, 3020703, 20837940.
7. Hess G, Keller U, Atta J, Buske C, Borchmann P, Medler C, Witzens-Harig M, Dreyling M. Temsirolimus in Combination with Bendamustine and Rituximab for the Treatment of Relapsed Mantle Cell and Follicular Lymphoma: Report on An Ongoing Phase I/II Trial. Blood 2011, 118(21):#2697.
8. Zoellner A-K, Bayerl S, Weinkauf M, Hiddemann W, Dreyling M. Temsirolimus and chemotherapy show additive effects and target independent cell programs (cell cycle, apoptosis) in diffuse large cell B cell lymphoma. Onkologie 2011, 34(6):#P271.
9. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999, 17(4):1244.